Circle Pharma
South San Francisco, US · Founded 2012 · Delaware corporation · 8 known investors
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
MP
Matthew P. JacobsonCo-founder
DJ
David J. EarpPresident & CEO
PP
Paul ParkExecutive Officer
SR
Scott R. LokeyDirector
DC
Douglas CrawfordDirector
WM
Walter MoosDirector
MJ
Matthew JacobsonDirector
TS
Thilo SchroederDirector
WH
Walter H. MoosDirector
JE
James EvangelistaDirector
SK
Stephen KelseyDirector
JJ
John JoseyDirector
Investors · 8
Berkeley CatalystBerkeley
Lifeforce CapitalChevy Chase · $500K – $5M
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
Nextech InvestZurich · $648K – $3.2M
Pandect BioventuresWoodsidevia Walter H. Moos · board
The Column GroupSan Francisco · $30Mvia Peter Svennilson · board
WI Harper GroupSan Francisco · $5M – $15M
Reported raises · per SEC filings
Form D private placements▶$92.4MraisedJan 2025 · 14 investors · OtherRule 506(b)
▶$92.4MraisedJan 2025 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Thilo SchroederDirector
- Stephen KelseyDirector
- David J. EarpExecutive Officer, Director
- Matthew P. JacobsonDirector
- Walter H. MoosDirector
- Paul ParkExecutive Officer
- James EvangelistaDirector
- John JoseyDirector
- Offering amount
- $117.4M
- Amount sold
- $92.4M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66.3MraisedMar 2022 · 20 investors · PharmaceuticalsRule 506(b)
▶$66.3MraisedMar 2022 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James EvangelistaDirector
- Thilo SchroederDirector
- John JoseyDirector
- Matthew JacobsonDirector
- Elton SatuskyExecutive Officer
- David EarpExecutive Officer, Director
- Walter MoosDirector
- Offering amount
- $66.3M
- Amount sold
- $66.3M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedMar 2020 · 7 investors · OtherRule 506(b)
▶$15MraisedMar 2020 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David J. EarpExecutive Officer, Director
- Elton SatuskyExecutive Officer
- Matthew P. JacobsonDirector
- John JoseyDirector
- Thilo SchroederDirector
- Peter SvennilsonDirector
- Cayla McEwenExecutive Officer
- Walter MoosDirector
- Offering amount
- $45M
- Amount sold
- $15M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedSep 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.8MraisedSep 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott R. LokeyDirector
- David J. EarpExecutive Officer, Director
- Douglas CrawfordDirector
- Walter MoosDirector
- Matthew JacobsonDirector
- Offering amount
- $6M
- Amount sold
- $3.8M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Circle Pharma Closes $90M Series D Financingfinsmes.com · 2024
- Circle Pharma Closes $90 Million Series D Financing to Advance Innovative Oral Macrocycle Therapies - Circle Pharmacirclepharma.com · 2024
- Lilly helps Circle round up $66M for intractable target R&D | Fierce Biotechfiercebiotech.com · 2021
- Circle Pharma raises $66 Million in Series C Financing - Circle Pharmacirclepharma.com · 2021
- Macrocycle Drug Discovery Company Circle Pharma Raises $45 Millionpulse2.com · 2020